Abstract
Stroke is a major cause of death and disability worldwide. Without improvements in prevention, the burden will increase during the next 20 years because of the ageing population, especially in developing countries. Major advances have occurred in secondary prevention during the past three decades, which demonstrate the broader potential to prevent stroke. We review the main medical treatments that should be considered for most patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, and draw attention to recent developments.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Acute Disease
-
Anticoagulants / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Atrial Fibrillation / complications*
-
Brain Ischemia / blood
-
Brain Ischemia / complications
-
Brain Ischemia / etiology
-
Cardiovascular Agents / therapeutic use*
-
Cholesterol, HDL / blood
-
Cholesterol, LDL / blood
-
Chronic Disease
-
Developing Countries / statistics & numerical data
-
Dyslipidemias / blood
-
Dyslipidemias / complications
-
Dyslipidemias / drug therapy
-
Fibrinolytic Agents / therapeutic use
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Hypolipidemic Agents / therapeutic use
-
Ischemic Attack, Transient / blood
-
Ischemic Attack, Transient / complications*
-
Ischemic Attack, Transient / drug therapy*
-
Ischemic Attack, Transient / etiology
-
Predictive Value of Tests
-
Prognosis
-
Risk Assessment
-
Risk Factors
-
Secondary Prevention
-
Stroke / blood
-
Stroke / epidemiology
-
Stroke / etiology*
-
Stroke / prevention & control*
-
Stroke / therapy
-
Time Factors
-
Triage
Substances
-
Anticoagulants
-
Antihypertensive Agents
-
Cardiovascular Agents
-
Cholesterol, HDL
-
Cholesterol, LDL
-
Fibrinolytic Agents
-
Hypolipidemic Agents